The biopharmaceutical firm secures $700 million through a public offering priced at $71 per share.
Cytokinetics has priced a $700 million stock offering at $71 per share, bolstering its capital position. The move follows recent advancements in its clinical pipeline, including late-stage drug candidates targeting cardiovascular and neuromuscular diseases.
The offering size exceeds prior equity raises, reflecting investor confidence amid ongoing trials. The company last raised funds in early 2023, though at a lower per-share valuation. Proceeds are earmarked for research, development, and potential commercialization efforts.
Shares of Cytokinetics (CYTK) traded slightly lower in after-hours activity, paring some gains from earlier sessions.